| Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Co.'s most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare hematological disease that impacts fetuses and newborns. Co. is evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2 clinical trial; and RLYB116, a subcutaneously administered inhibitor of complement factor 5. The RLYB average annual return since 2021 is shown above.
The Average Annual Return on the RLYB average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RLYB average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RLYB average annual return calculation with any dividends reinvested as applicable (on ex-dates).